摘要
目的探讨急性心肌梗死应用瑞舒伐他汀的治疗效果和预后影响。方法 80例急性心肌梗死患者,随机分为对照组和观察组,每组40例。对照组患者接受基础性治疗同时接受螺内酯治疗,观察组患者在基础性治疗同时接受瑞舒伐他汀治疗,比较两组患者治疗效果。结果治疗后,观察组患者血超敏C反应蛋白为(27.3±3.3)mg/L,低密度脂蛋白为(2.5±0.3)mmol/L,对照组患者血超敏C反应蛋白为(12.6±1.8)mg/L,低密度脂蛋白为(13.5±0.5)mmol/L,观察组各项指标情况均优于对照组,差异具有统计学意义(P<0.05)。观察组患者再梗死率及心律失常发生率均少于对照组,差异具有统计学意义(P<0.05)。结论在急性心肌梗死患者中应用瑞舒伐他汀进行早期治疗,能够使相关致病因子有效降低,使得患者预后效果得到显著改善,具有较高的临床推广价值。
Objective To investigate curative effect by rosuvastatin applied in the treatment of acutemyocardial infarction and its influence on prognosis.Methods A total of80patients with acute myocardialinfarction were randomly divided into control group and observation group,with40cases in each group.Thecontrol group received additional spirolactone to basic therapy,and the observation group received rosuvastatinto basic therapy.Comparison was made on curative effects between the two groups.Results After treatment,the observation group had high-sensitivity C-reactive protein as(27.3±3.3)mg/L,and low density lipoproteinas(2.5±0.3)mmol/L.The control group had high-sensitivity C-reactive protein as(12.6±1.8)mg/L,and lowdensity lipoprotein as(13.5±0.5)mmol/L.The observation group had all better indexes than the control group,and thedifference had statistical significance(P<0.05).The observation group had lower reinfarction and arrhythmia rate thanthe control group,and their difference had statistical significance(P<0.05).Conclusion Implement of rosuvastatinas early therapy in the treatment of acute myocardial infarction patients can effectively lower related pathogenicfactors and remarkably improve prognosis effect in patients.This method contains high value for clinicalpromotion.
作者
李保军
LI Bao-jun(Shenyang Emergency Center, Shenyang 110006, China)
出处
《中国现代药物应用》
2017年第4期95-96,共2页
Chinese Journal of Modern Drug Application
关键词
瑞舒伐他汀
急性心肌梗死
治疗效果
Rosuvastatin
Acute myocardial infarction
Curative effect
